A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma

Trial Profile

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Interferon alpha-2b; Interferon alpha-2b
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results assessing safety and preliminary Recurrence-free survival (RFS), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2017 Interim analysis from this trial published in a Bristol-Myers Squibb Media Release.
    • 27 Jul 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top